Found: 50
Select item for more details and to access through your institution.
A systematic approach to the management of patients with brain metastases of known or unknown primary site.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 1, doi. 10.1007/s00280-011-1775-9
- By:
- Publication type:
- Article
Population pharmacokinetics of PM00104 (Zalypsis((R))) in cancer patients.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Population pharmacokinetics of PM00104 (Zalypsis) in cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 15, doi. 10.1007/s00280-011-1644-6
- By:
- Publication type:
- Article
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 25, doi. 10.1007/s00280-011-1670-4
- By:
- Publication type:
- Article
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 35, doi. 10.1007/s00280-011-1663-3
- By:
- Publication type:
- Article
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 43, doi. 10.1007/s00280-011-1664-2
- By:
- Publication type:
- Article
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 51, doi. 10.1007/s00280-011-1672-2
- By:
- Publication type:
- Article
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 57, doi. 10.1007/s00280-011-1669-x
- By:
- Publication type:
- Article
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 65, doi. 10.1007/s00280-011-1673-1
- By:
- Publication type:
- Article
The marine sponge toxin agelasine B increases the intracellular Ca concentration and induces apoptosis in human breast cancer cells (MCF-7).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 71, doi. 10.1007/s00280-011-1677-x
- By:
- Publication type:
- Article
Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 85, doi. 10.1007/s00280-011-1675-z
- By:
- Publication type:
- Article
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 91, doi. 10.1007/s00280-011-1668-y
- By:
- Publication type:
- Article
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 99, doi. 10.1007/s00280-011-1678-9
- By:
- Publication type:
- Article
Hematologic adverse events associated with temozolomide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 107, doi. 10.1007/s00280-011-1679-8
- By:
- Publication type:
- Article
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 115, doi. 10.1007/s00280-011-1680-2
- By:
- Publication type:
- Article
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C-erythromycin breath test and the antipyrine clearance test.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 125, doi. 10.1007/s00280-011-1676-y
- By:
- Publication type:
- Article
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 137, doi. 10.1007/s00280-011-1674-0
- By:
- Publication type:
- Article
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 145, doi. 10.1007/s00280-011-1682-0
- By:
- Publication type:
- Article
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 155, doi. 10.1007/s00280-011-1662-4
- By:
- Publication type:
- Article
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 165, doi. 10.1007/s00280-011-1667-z
- By:
- Publication type:
- Article
Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 173, doi. 10.1007/s00280-011-1681-1
- By:
- Publication type:
- Article
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 185, doi. 10.1007/s00280-011-1684-y
- By:
- Publication type:
- Article
5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 195, doi. 10.1007/s00280-011-1686-9
- By:
- Publication type:
- Article
Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 207, doi. 10.1007/s00280-011-1692-y
- By:
- Publication type:
- Article
Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 215, doi. 10.1007/s00280-011-1689-6
- By:
- Publication type:
- Article
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 221, doi. 10.1007/s00280-011-1688-7
- By:
- Publication type:
- Article
Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 229, doi. 10.1007/s00280-011-1687-8
- By:
- Publication type:
- Article
Different combination schedules of gemcitabine with endostar affect antitumor efficacy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 239, doi. 10.1007/s00280-011-1695-8
- By:
- Publication type:
- Article
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 247, doi. 10.1007/s00280-011-1659-z
- By:
- Publication type:
- Article
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 253, doi. 10.1007/s00280-011-1698-5
- By:
- Publication type:
- Article
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
- Published in:
- 2012
- By:
- Publication type:
- Report
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
- Published in:
- 2012
- By:
- Publication type:
- Report
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 1, p. 281, doi. 10.1007/s00280-011-1754-1
- By:
- Publication type:
- Article